ArticleScientific reports2025
A novel 5-protein kinase risk signature for predicting glioma prognosis and immunotherapy responsiveness.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Glycolysis and T cell-associated gene signature predicts prognosis and therapeutic responses in pancreatic cancer.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Glioma, among the most prevalent and heterogeneous intracranial malignancies, exhibit dismal prognoses despite advances in molecular diagnostics. Protein kinases, critical regulators of tumorigenesis, remain underexplored as systematic prognostic markers in glioma. In this study, we identified 29 differentially expressed protein kinases in TCGA (LGG and GBM) and GEO (GSE16011) databases. These dysregulated kinases were enriched in biological functions and signaling pathways related to glioma progression. Through univariate Cox, LASSO, and multivariate Cox regression, we developed a novel protein kinase prognostic risk signature comprising CAMKK2, PAK1, AK5, WEE1, and CDK4 and validated its performance to predict outcomes. We also constructed a nomogram integrating clinical characteristics and the kinase signature, which showed a high accuracy in predicting overall survival (OS) of glioma patients in TCGA, CGGA and GSE43378 cohorts. Furthermore, GSEA analysis based on risk scores revealed that various signaling pathways associated with glioma genesis and progression were enriched in the high-risk group. Immune cell infiltration analysis displayed high-risk group was characterized by a higher infiltration level of stromal and immune cells and upregulation of key immune checkpoint genes. Finally, we confirmed the protein expression of five protein kinases in glioma samples and normal samples. In conclusion, we developed a novel prognostic signature for glioma. The signature not only has potential as a prognostic biomarker but may also serve as a therapeutic target for glioma, offering new insights into glioma treatment and prognosis assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.